Inpixon
NASDAQ:XTIA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inpixon
NASDAQ:XTIA
|
US |
|
Altius Renewable Royalties Corp
TSX:ARR
|
CA |
|
P
|
Provention Bio Inc
F:2VB
|
US |
|
I
|
IBI Investment House Ltd
TASE:IBI
|
IL |
|
T
|
TMC Industrial PCL
SET:TMC
|
TH |
|
Stria Lithium Inc
F:S35A
|
CA |
|
A
|
Aju IB Investment Co Ltd
KOSDAQ:027360
|
KR |
|
A
|
Asia Medical & Agricultural Laboratory & Research Center PCL
SET:AMARC
|
TH |
|
Felix Group Holdings Ltd
ASX:FLX
|
AU |
|
R
|
Rectitude Holdings Ltd
NASDAQ:RECT
|
SG |
|
C
|
CTI Biopharma Corp
F:CEPS
|
US |
Wall Street
Price Targets
XTIA Price Targets Summary
Inpixon
According to Wall Street analysts, the average 1-year price target for
XTIA
is 3.06 USD
with a low forecast of 3.03 USD and a high forecast of 3.15 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is XTIA's stock price target?
Price Target
3.06
USD
According to Wall Street analysts, the average 1-year price target for
XTIA
is 3.06 USD
with a low forecast of 3.03 USD and a high forecast of 3.15 USD.
What is Inpixon's Revenue forecast?
Projected CAGR
291%
For the last 12 years the
compound annual growth rate for
Inpixon's revenue is
-2%.
The projected
CAGR
for the next 3 years is
291%.
